Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID-19 pandemic: A population-based, nation-wide study
Research output: Contribution to journal › Letter › Research › peer-review
Standard
Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID-19 pandemic : A population-based, nation-wide study. / Faitová, Tereza; Brieghel, Christian; Eriksson, Frank; Niemann, Carsten U.
In: HemaSphere, Vol. 8, No. 3, e57, 2024.Research output: Contribution to journal › Letter › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID-19 pandemic
T2 - A population-based, nation-wide study
AU - Faitová, Tereza
AU - Brieghel, Christian
AU - Eriksson, Frank
AU - Niemann, Carsten U
PY - 2024
Y1 - 2024
N2 - Patients with B-cell-derived malignancies are at increased risk of severe coronavirus disease 2019 (COVID-19) due to the inherent immune dysfunction and/or treatment. To protect patients in general and patients with B-cell-derived malignancies in particular from COVID-19, management of these patients was changed toward virtual consultations during the pandemic. Whether the COVID-19 pandemic itself and/or changes in management have led to excess mortality among hematological patients during the COVID-19 pandemic in Denmark has not yet been investigated.
AB - Patients with B-cell-derived malignancies are at increased risk of severe coronavirus disease 2019 (COVID-19) due to the inherent immune dysfunction and/or treatment. To protect patients in general and patients with B-cell-derived malignancies in particular from COVID-19, management of these patients was changed toward virtual consultations during the pandemic. Whether the COVID-19 pandemic itself and/or changes in management have led to excess mortality among hematological patients during the COVID-19 pandemic in Denmark has not yet been investigated.
U2 - 10.1002/hem3.57
DO - 10.1002/hem3.57
M3 - Letter
C2 - 38505245
VL - 8
JO - HemaSphere
JF - HemaSphere
SN - 2572-9241
IS - 3
M1 - e57
ER -
ID: 385889080